Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Replimune Group (Nasdaq: REPL), a clinical stage biotechnology company focused on developing novel oncolytic immunotherapies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will deliver a presentation on Monday, January 13, 2025, at 2:15 PM PT.

The presentation will be accessible through a simultaneous webcast in the Investors section of Replimune's website at replimune.com. For those unable to attend live, a replay option will remain available for 30 days after the conference.

News Market Reaction

-1.20%

1 alert

-1.20% News Effect

On the day this news was published, REPL declined 1.20%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 2:15 PM PT.

A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be available for 30 days following the conference.

About Replimune 
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit replimune.com.

Investor Inquiries
Chris Brinzey
ICR Healthcare
339.970.2843
chris.brinzey@icrhealthcare.com

Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com

FAQ

When is Replimune (REPL) presenting at the 2025 J.P. Morgan Healthcare Conference?

Replimune (REPL) will present at the J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 2:15 PM PT.

How long will the replay of Replimune's (REPL) J.P. Morgan Healthcare Conference presentation be available?

The replay of Replimune's presentation will be available for 30 days following the conference.

Where can investors watch Replimune's (REPL) J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation through a simultaneous webcast in the Investors section of Replimune's website at replimune.com.

What type of therapies is Replimune (REPL) developing as presented at the J.P. Morgan Healthcare Conference?

Replimune is developing novel oncolytic immunotherapies as a clinical stage biotechnology company.